<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034485</url>
  </required_header>
  <id_info>
    <org_study_id>LIB003-003</org_study_id>
    <nct_id>NCT04034485</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH</brief_title>
  <official_title>Randomized, Open-Label, Cross-Over, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in Homozygous Familial Hypercholesterolemia Patients on Stable Lipid-Lowering Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LIB Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LIB Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety, tolerability and LDL-C response after 24 Weeks of monthly (every 4&#xD;
      weeks [Q4W]) subcutaneous (SC) dosing of LIB003 300 mg with monthly (Q4W) SC dosing of 420 mg&#xD;
      evolocumab (Repatha®) in patients with HoFH on stable diet and oral LDL-C-lowering drug&#xD;
      therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with verified HoFH on stable and continuing doses of oral lipid lowering therapy&#xD;
      will be randomized to either evolocumab 420 mg Q4W or LIB003 300 mg Q4W for 24 weeks (Period&#xD;
      A). At Week 24, subjects will be crossed over to LIB003 if they were on evolocumab and vice&#xD;
      versa for the next 24 weeks (Period B).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 7, 2019</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>open label, randomized, cross-over</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>treatment is open label but lipid results are masked to participant, investigator and sponsor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction in Low Density Lipoprotein Cholesterol (LDL-C) at week 24</measure>
    <time_frame>baseline to 24 weeks on each treatment</time_frame>
    <description>Change in serum LDL-C from baseline after 24 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>baseline to 24 weeks on each treatment</time_frame>
    <description>safety and tolerability will be based on the incidence and severity of treatment emergent adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent reduction in lipoprotein (a) [Lp(a)] at week 24</measure>
    <time_frame>baseline to 24 weeks on each treatment</time_frame>
    <description>Change in serum Lp(a) from baseline after 24 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent reduction in apolipoprotein B (Apo B) at week 24</measure>
    <time_frame>baseline to 24 weeks on each treatment</time_frame>
    <description>Change in serum Apo B from baseline after 24 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Presence of anti LIB003 antibodies (ADAs)</measure>
    <time_frame>baseline to 24 weeks</time_frame>
    <description>Measurement of ADAs at baseline and various intervals</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>LIB003 (lerodalcibep)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg SC Q4W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>evolocumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>420 mg SC Q4W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lerodalcibep</intervention_name>
    <description>PCSK9 inhibitor</description>
    <arm_group_label>LIB003 (lerodalcibep)</arm_group_label>
    <other_name>LIB003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>evolocumab</intervention_name>
    <description>PCSK9 inhibitor</description>
    <arm_group_label>evolocumab</arm_group_label>
    <other_name>Repatha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HoFH diagnosed clinically and confirmed by genotyping&#xD;
&#xD;
          -  Weight of &gt;30 kg and body mass index (BMI) &gt;17 and &lt;40 kg/m2&#xD;
&#xD;
          -  stable diet and lipid-lowering oral therapies for at least 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  mipomersen within 6 months of screening;&#xD;
&#xD;
          -  LDL or plasma apheresis &lt;2 months prior to randomization&#xD;
&#xD;
          -  history of non-response to PCSK9 mAb or presence of receptor negative/null LDLR&#xD;
             activity expected to result in non-response to PCSK9 inhibition&#xD;
&#xD;
          -  prior or active clinical condition or acute and/or unstable systemic disease&#xD;
             compromising subject inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan A Stein, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>LIB Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic &amp; Atherosclerosis Research Center (MARC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VMMC &amp; Safdarjung Hospital</name>
      <address>
        <city>Delhi</city>
        <state>NCT</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIMS Hospital Pvt. Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.B. Pant Institute of Postgraduate Medical Education &amp; Research</name>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>12000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital,</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipid Clinic, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0586</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carbohydrate and Lipid Metabolism Research Unit</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Lipidology, Department of Medicine University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical School</name>
      <address>
        <city>İzmir</city>
        <state>Bornova</state>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Afyonkarahisar Health Sciences University</name>
      <address>
        <city>Afyon</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Israel</country>
    <country>Norway</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDL cholesterol</keyword>
  <keyword>PCSK9 inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

